The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Abbott introduced a revolutionary new device, FreeStyle Navigator, designed to improve the lives of the world’s more than 500 ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Thursday, Abbott Laboratories ABT said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.

ABBOTT PARK, Ill. - Abbott has issued a recall for certain FreeStyle Libre 3 sensors due to a risk for inaccurate high glucose readings.

Abbott Diabetes Care, Inc. is recalling its FreeStyle Libre 3 sensors after finding a small number of the sensors may provide incorrect high glucose readings, which, if undetected may pose ...

Some better-ranked stocks in the broader medical space are TransMedix Group TMDX, Veracyte VCYT and Boston Scientific BSX. While TransMedix Group and Veracyte currently sport a Zacks Rank #1 (Strong ...

Four years later they launched FreeStyle Libre, a reimagined continuous glucose monitoring (CGM) system in which an even smaller sensor applied to a patient’s arm sends data directly to a ...